Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis

M Drolet, É Bénard, N Pérez, M Brisson, H Ali, MC Boily… - The Lancet, 2019 - thelancet.com
Background More than 10 years have elapsed since human papillomavirus (HPV)
vaccination was implemented. We did a systematic review and meta-analysis of the …

Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis

M Drolet, É Bénard, MC Boily, H Ali… - The Lancet infectious …, 2015 - thelancet.com
Background Human papillomavirus (HPV) vaccination programmes were first implemented
in several countries worldwide in 2007. We did a systematic review and meta-analysis to …

Prevalence of HPV after introduction of the vaccination program in the United States

LE Markowitz, G Liu, S Hariri, M Steinau, EF Dunne… - …, 2016 - publications.aap.org
BACKGROUND: Since mid-2006, human papillomavirus (HPV) vaccination has been
recommended for females aged 11 to 12 years and through 26 years if not previously …

Human papillomavirus molecular biology

ME Harden, K Munger - Mutation Research/Reviews in Mutation Research, 2017 - Elsevier
Human papillomaviruses are small DNA viruses with a tropism for squamous epithelia. A
unique aspect of human papillomavirus molecular biology involves dependence on the …

Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study

SN Tabrizi, JML Brotherton, JM Kaldor… - The Lancet infectious …, 2014 - thelancet.com
Background After the introduction of a quadrivalent human papillomavirus (HPV) vaccination
programme in Australia in April, 2007, we measured the prevalence of vaccine-targeted and …

Human papillomavirus laboratory testing: the changing paradigm

EM Burd - Clinical microbiology reviews, 2016 - Am Soc Microbiol
High-risk human papillomaviruses (HPVs) cause essentially all cervical cancers, most anal
and oropharyngeal cancers, and some vaginal, vulvar, and penile cancers. Improved …

HPV-FASTER: broadening the scope for prevention of HPV-related cancer

FX Bosch, C Robles, M Diaz, M Arbyn… - Nature reviews Clinical …, 2016 - nature.com
Human papillomavirus (HPV)-related screening technologies and HPV vaccination offer
enormous potential for cancer prevention, notably prevention of cervical cancer. The …

Present status of human papillomavirus vaccine development and implementation

R Herrero, P González, LE Markowitz - The Lancet Oncology, 2015 - thelancet.com
Oncogenic human papillomavirus (HPV) infection is the cause of nearly all cervical cancers
and a proportion of other anogenital and oropharyngeal cancers. A bivalent vaccine …

Next generation prophylactic human papillomavirus vaccines

JT Schiller, M Müller - The lancet oncology, 2015 - thelancet.com
The two licensed bivalent and quadrivalent human papillomavirus (HPV) L1 (the major
papillomavirus virion protein) virus-like particle (VLP) vaccines are regarded as safe …

Prevalence of human papillomavirus genotypes among African women with normal cervical cytology and neoplasia: a systematic review and meta-analysis

RK Ogembo, PN Gona, AJ Seymour, HSM Park… - PloS one, 2015 - journals.plos.org
Background Several meta-analyses confirmed the five most prevalent human papillomavirus
(HPV) strains in women with and without cervical neoplastic diseases are HPV16, 18, 31 …